Older adults (typically defined as age 65+) carry a substantial burden of mental health need — late-life depression, post-traumatic stress disorder (including aging veterans), end-of-life distress in the context of advanced or terminal illness, generalized anxiety, and treatment-resistant depression that has accumulated across decades of partial response. Yet the pivotal psychedelic-assisted therapy RCT base has historically excluded older adults — most psilocybin and MDMA trials capped enrolment at age 65, and where older adults were included it was typically in narrowly-defined cancer-related distress populations. This article is a Canadian geriatric guide to what the evidence does — and does not — support for psychedelic-assisted therapy in older adults: comprehensive geriatric assessment first, polypharmacy and pharmacokinetic considerations, cardiovascular and cognitive screening, and an honest framing that not all older adults are appropriate candidates. Spravato (esketamine) is Health Canada-approved for TRD with older adults included in the pivotal label population. Off-label ketamine has the Anand 2023 ELEKT-D evidence in TRD with older adults represented. Psilocybin under the Special Access Program (SAP) is investigational; Griffiths 2016 and Ross 2016 end-of-life distress trials are the most directly applicable older-adult evidence.

Key takeaways

Older adults (65+) carry substantial mental health need — late-life depression, PTSD (post-traumatic stress disorder; aging veterans), end-of-life distress, anxiety, TRD (treatment-resistant depression) that has accumulated across decades.

Late-life depression has specific clinical features: medical comorbidity load, executive dysfunction, anhedonia, somatic presentation; older men carry the highest suicide rates of any Canadian demographic.

Polypharmacy is the dominant geriatric safety variable — older adults take more medications, with more interaction risk. Beers Criteria potentially-inappropriate medications must be reviewed.

Cardiovascular screening is essential — ketamine produces acute BP/HR rises; psilocybin and MDMA produce cardiovascular load. Older adults have higher baseline cardiovascular comorbidity.

Cognitive screening matters — pre-existing cognitive impairment, dementia, and delirium risk shift the risk-benefit calculus substantially.

Hepatic and renal clearance changes with age affect ketamine and psilocybin pharmacokinetics.

RCT evidence base in older adults is limited — most psilocybin/MDMA trials capped at age 65 (Goodwin 2022 included up to age 65); end-of-life distress trials (Griffiths 2016, Ross 2016) included older cancer patients; Anand 2023 ELEKT-D included older TRD patients with upper-age limits varying.

Comprehensive geriatric assessment (CGA) — a multi-domain evaluation covering medical history, functional status, cognition, social context, and medications — is the appropriate clinical foundation.

Family/caregiver involvement is meaningful — caregiver burden and caregiver mental health are part of the clinical picture.

Long-term care settings are typically not appropriate for psychedelic-assisted therapy; community or specialty outpatient settings are.

Geriatric psychiatry consultation should be the default for any complex case.

Coverage pathways: Quebec RAMQ (Farzin/Stephan precedent) applies regardless of age; VAC for older veterans; public hospital ketamine programs (Edmonton Misericordia/Grey Nuns, Vancouver UBC Hospital).

Why older adults are a distinct clinical population

The "65+" boundary is administrative; biologically and clinically, the relevant variables are medical comorbidity, polypharmacy, functional status, cognitive reserve, and pharmacokinetic shifts. A robust 72-year-old with no comorbidities and four medications looks very different from a frail 68-year-old with five chronic conditions, twelve medications, and mild cognitive impairment. Geriatric medicine treats functional age and comorbidity, not chronological age.

Older adults in Canada represent ~18% of the population (Statistics Canada) and the share is growing. Mental health need in this group is substantial:

Major depressive disorder: prevalence in community-dwelling older adults ~5–10%; in long-term care 14–42%
PTSD: aging veterans, Holocaust survivors, residential school survivors, lifetime trauma exposure cohorts
End-of-life distress: existential distress, demoralization, anxiety in advanced and terminal illness — substantially overlaps with the older-adult population
Generalized anxiety, chronic pain, complicated grief — all elevated in older adults

Older men carry the highest suicide rates of any Canadian demographic group (Public Health Agency of Canada / Statistics Canada). This is a meaningful clinical priority.

Late-life depression — specific clinical features

Late-life depression is not just "depression in older people." Specific features:

Higher medical comorbidity load — cardiovascular disease, diabetes, neurodegenerative conditions
Executive dysfunction — slowed processing, difficulty with planning; the "depression-executive dysfunction syndrome"
Somatic presentation — pain, sleep disturbance, fatigue may dominate over reported sad mood
Vascular depression — small-vessel cerebrovascular changes contribute to depressive presentation
Higher suicide risk in older men — completion rates substantially above other demographics
Treatment resistance — accumulated across decades of partial response to multiple antidepressant trials

CANMAT late-life depression guidelines and the Canadian Coalition for Seniors' Mental Health (CCSMH) provide the standard-of-care framework. Psychedelic-assisted therapy is not first-line; it is considered after established treatments have been adequately trialled.

Geriatric pharmacology — the safety foundation

Polypharmacy

Older adults take more medications. Polypharmacy (often defined as ≥5 concurrent medications) is associated with increased adverse drug events, interactions, and falls. Beers Criteria (American Geriatrics Society) catalogs potentially-inappropriate medications for older adults — a comprehensive review is foundational before adding ketamine, esketamine, or any SAP-pathway psychedelic.

For psychedelic-assisted therapy specifically:

Anticholinergic burden (Beers-flagged TCAs, oxybutynin, diphenhydramine) — additive cognitive and delirium risk
Benzodiazepines and Z-drugs — Beers-flagged in older adults; sedation interactions with ketamine
Opioids — additive sedation; specific interactions with ketamine
Antihypertensives — important to know baseline BP control; ketamine produces acute BP rises
MAOIs — absolute contraindication with serotonergic psychedelics (psilocybin, MDMA)
Lithium and serotonergic agents — interaction considerations with psilocybin/MDMA
QT-prolonging medications — interaction with ketamine, MDMA

Cardiovascular considerations

Ketamine and esketamine produce acute increases in blood pressure and heart rate (typical peak ~30 minutes, resolving over 1–2 hours). The Spravato product monograph specifies BP monitoring; uncontrolled hypertension is a contraindication. In older adults with cardiovascular comorbidity this is a primary screening variable.
Psilocybin produces sympathomimetic load — modest BP/HR elevation, occasional vasovagal phenomena.
MDMA produces substantial cardiovascular load — sustained BP/HR elevation across the dosing window. MDMA RCT inclusion criteria typically exclude significant cardiovascular disease.
Older adults have higher prevalence of hypertension, coronary disease, atrial fibrillation, heart failure, valvular disease, aortic disease — all of which require explicit cardiovascular assessment before psychedelic-assisted therapy.

Cognitive considerations

Pre-existing cognitive impairment — mild cognitive impairment (MCI), dementia. Capacity to consent must be established. Dissociative experiences during ketamine administration may be more difficult to integrate; psilocybin "challenging experiences" carry higher distress potential.
Delirium risk — older adults have elevated delirium risk with sedation, dehydration, sleep disruption, polypharmacy. Ketamine sessions and psilocybin dosing days carry a non-zero delirium risk in vulnerable older adults.
Cognitive screening — MMSE or MoCA at intake; functional cognition assessment.

Hepatic and renal considerations

Ketamine is hepatically metabolized (CYP3A4, CYP2B6) to norketamine. Hepatic impairment affects clearance and may produce extended dissociative effects.
Renal function — eGFR declines with age; renal clearance affects medication elimination and contributes to polypharmacy interaction risk.
Psilocybin is hepatically dephosphorylated to psilocin then conjugated; hepatic considerations apply.
Frailty and sarcopenia — body composition changes alter weight-based dosing assumptions.

RCT evidence in older adults — what we have and don't have

The exclusion problem

Most pivotal psychedelic-assisted therapy RCTs excluded patients ≥65 historically. Trial sponsors typically capped age to manage cardiovascular and cognitive risk during the regulatory program. This means the direct RCT evidence base in older adults is limited — and patients, families, and clinicians need to be honest about that gap.

Goodwin 2022 COMP001 NEJM psilocybin TRD — included up to age 65 (some sites slightly above)
Carhart-Harris 2021 NEJM psilocybin vs escitalopram — typical adult cap; older adults under-represented
Mitchell 2021/2023 MAPP1/MAPP2 MDMA-AT PTSD — older adults under-represented
Spravato (esketamine) program — older adults included in TRD population. Phase 3 program did not exclude on age ceiling, and TRANSFORM-3 specifically studied esketamine in older adults (≥65) with TRD, showing safety and efficacy signals consistent with the broader TRD population.
Anand 2023 ELEKT-D NEJM ketamine vs ECT in TRD — older TRD patients included; specific upper-age limit varies by site protocol; non-inferiority of ketamine to ECT is the headline result.

End-of-life distress — the most directly applicable older-adult evidence

The end-of-life distress population overlaps substantially with the older-adult population — most patients with advanced cancer, advanced organ failure, or terminal illness in cancer-related distress trials were older adults.

Griffiths RR, Johnson MW, Carducci MA, et al. 2016 (PMID 27909164) — Johns Hopkins RCT of psilocybin in cancer-related anxiety and depression; older cancer patients well represented; substantial decreases in depression and anxiety sustained at 6-month follow-up.
Ross S, Bossis A, Guss J, et al. 2016 (PMID 27909165) — NYU RCT of psilocybin in cancer-related distress; older cancer patients well represented; rapid and sustained reduction in depression and anxiety.

These two trials are the most directly applicable older-adult evidence base — and they shape the current Health Canada SAP psilocybin pathway, which has approved end-of-life distress applications since 2020.

For more detail, see End-of-Life Distress and Psychedelic-Assisted Therapy and the Psilocybin Therapy in Canada hub.

Comprehensive geriatric assessment — the appropriate foundation

The Comprehensive Geriatric Assessment (CGA) is the standard-of-care multi-domain framework for evaluating older adults. For psychedelic-assisted therapy candidacy, the CGA-informed pre-treatment workup includes:

Medical: full medical history; cardiovascular workup (ECG; echocardiogram if indicated); hepatic and renal function; HbA1c; thyroid; B12/folate
Medication review: full medication reconciliation; Beers Criteria review; deprescribing where appropriate
Cognitive: MoCA/MMSE; capacity assessment; dementia screening
Functional: ADLs/IADLs; mobility; falls risk
Mental health: full psychiatric history; suicidality assessment; substance use; trauma history
Social: living situation; caregivers; social support; financial resources; advance care planning
Goals: what does the patient want from treatment? Symptom relief? Quality of life? End-of-life integration?

Many older adults will not be appropriate candidates for psychedelic-assisted therapy after CGA. That is an honest and clinically appropriate outcome — and it is the foundation of safe practice.

Family and caregiver involvement

Older-adult care is inherently family/caregiver-involving in a way that adult-onset depression in younger patients often is not. Considerations:

Capacity and consent — capacity must be established; family/caregiver involvement does not replace patient consent
Caregiver burden — providing care to an older adult with significant mental health need is associated with substantial caregiver distress; caregiver mental health is part of the clinical picture
Caregiver role in preparation and integration — particularly for psilocybin SAP end-of-life distress sessions, family presence and post-session support are clinically meaningful
Advance care planning — particularly relevant when the older adult has terminal or advanced illness

Settings — where psychedelic-assisted therapy is and isn't appropriate

Community outpatient (specialty clinic): the standard setting for ketamine, esketamine, and SAP psilocybin in older adults
Hospital outpatient: appropriate for higher-acuity cases (e.g., Edmonton Misericordia/Grey Nuns public ketamine program; Vancouver UBC Hospital VCH program)
Palliative care / hospice: increasingly relevant for SAP psilocybin end-of-life distress; coordination with palliative team essential
Long-term care (nursing homes): typically not an appropriate setting for psychedelic-assisted therapy. Staff resources, monitoring infrastructure, and clinical context are not designed for this. SAP psilocybin sessions are not delivered in LTC.
At-home: not typical for older-adult psychedelic-assisted therapy; supervision requirements are too high.

Geriatric psychiatry consultation

The default for any complex older-adult case considering psychedelic-assisted therapy should include geriatric psychiatry consultation:

Specialty assessment for capacity, comorbidity, medication interactions
Coordination with primary care and any other specialists (cardiology, neurology, palliative care)
Risk stratification for cognitive and cardiovascular adverse events
Ongoing follow-up and integration support

In Canada, geriatric psychiatry capacity is concentrated in academic centres (Toronto, Vancouver, Montreal, Edmonton, Calgary, Halifax). Wait times can be long; family physicians and general psychiatrists often play the central role with geriatric psychiatry consultation as adjunct.

Canadian access pathways for older adults

Spravato (esketamine)

Spravato is Health Canada-approved for TRD; older adults are included in the pivotal label population. Coverage pathways:

PSHCP (federal public servants and pensioners — many older adults retain coverage post-retirement): Form M7520 prior auth pathway
Private insurance (retiree benefit plans): Manulife, Sun Life, Green Shield typically cover with prior auth
Provincial drug plans for seniors: ODB EAP/SADIE in Ontario rare; BC Fair PharmaCare non-benefit; Alberta ABC seniors plan non-benefit; Quebec RAMQ public drug plan non-benefit

For more detail, see Spravato Coverage — PSHCP and Canada Life.

Off-label ketamine

Out-of-pocket dominantly for older adults: ~$400–$1,500/session
VAC for older veterans (a substantial subset of the 65+ population): established case-by-case pathway for service-related conditions including PTSD and depression
Public hospital programs: Edmonton Misericordia/Grey Nuns and Vancouver UBC Hospital VCH are publicly-funded outpatient psychiatric ketamine programs that accept older adults meeting clinical criteria — these are the pathways with no out-of-pocket cost
Workers' compensation: not typically applicable for the 65+ population unless ongoing claim from prior working life

For more detail, see VAC Coverage for Psychedelic-Assisted Therapy and Edmonton Misericordia/Grey Nuns Public Ketamine.

Psilocybin SAP

End-of-life distress — primary SAP-approved indication; older cancer patients are the dominant population
Treatment-resistant depression after conventional failure — secondary SAP-approved indication; older adults with extensive treatment history are candidates
Quebec RAMQ Farzin/Stephan precedent (December 2022) applies regardless of age — older Quebec residents with SAP-approved psilocybin and end-of-life distress have a public-funding pathway through the RAMQ exception process
Filament Health no-charge SAP supply — particularly relevant for older adults on fixed income

For more detail, see Quebec RAMQ Coverage for Psychedelic Therapy and the Psilocybin Therapy in Canada hub.

What the evidence does NOT say

No psychedelic-assisted therapy is indicated specifically by age. Older adults who are appropriate candidates after CGA are appropriate; chronological age alone neither qualifies nor disqualifies.
The RCT evidence base in older adults is limited — Goodwin 2022, Carhart-Harris 2021, Mitchell 2021/2023 historically capped at 65. Inferences from younger-adult populations should be made carefully.
Spravato older-adult evidence (TRANSFORM-3) is real but modest — efficacy signals consistent with broader TRD population, but the older-adult literature is smaller.
End-of-life distress trial inclusions (Griffiths 2016, Ross 2016) are not generalizable to all older adults — the studied population was specifically cancer patients with anxiety/depression. Healthy older adults with TRD are a different population.
Polypharmacy is the dominant safety variable — many older adults will not be appropriate candidates because of medication burden alone.
Cognitive impairment shifts the calculus — capacity, integration ability, and delirium risk all change with cognitive status.
Long-term care settings are not appropriate — psychedelic-assisted therapy is a specialty outpatient intervention, not a nursing-home intervention.
Comprehensive geriatric assessment first — this is the foundation, and many older adults will have it indicate that other interventions are higher-priority.

How ATMA CENA works with older adults

ATMA CENA's older-adult pathway:

Comprehensive intake: full geriatric-informed assessment — medical history, full medication reconciliation, cardiovascular and cognitive screening, functional status, social context, advance care planning where relevant
Geriatric psychiatry consultation: facilitated where complexity warrants
Coordinated care: ATMA CENA can layer alongside existing primary care, geriatric specialist, palliative care team
Family/caregiver involvement: supported throughout preparation, dosing day, and integration
Honest framing: many older adults will not be appropriate candidates and will be routed to other interventions
No long-term care setting delivery: psychedelic-assisted therapy is delivered in community outpatient or hospital outpatient settings only

For more detail, see End-of-Life Distress and Psychedelic-Assisted Therapy.

Frequently asked questions

Am I "too old" for psychedelic-assisted therapy? Chronological age alone is not the determining factor. Comprehensive geriatric assessment — medical comorbidity, polypharmacy, cognition, functional status — determines candidacy. Many older adults are appropriate candidates after assessment; many are not.

What's the strongest evidence for older adults? The Griffiths 2016 and Ross 2016 end-of-life distress trials (psilocybin in cancer patients) included older adults and remain the most directly applicable RCT base. Spravato's TRANSFORM-3 included older TRD adults. Most other psychedelic RCTs capped at age 65.

Will my heart medications interact with ketamine? This requires individual review. Ketamine produces acute BP/HR rises; well-controlled hypertension is typically not a contraindication, but uncontrolled hypertension or significant cardiovascular disease may be. Specific medication interactions are reviewed at intake.

I take many medications — does that disqualify me? Polypharmacy raises interaction risk but does not automatically disqualify. Beers Criteria review and medication reconciliation are part of the workup; some medications may be deprescribed or adjusted.

I have mild cognitive impairment — is this safe? Pre-existing cognitive impairment shifts the risk-benefit calculus. Capacity to consent must be established; integration of dissociative or psychedelic experiences may be more difficult; delirium risk is elevated. Geriatric psychiatry consultation is recommended.

My spouse is in long-term care — can they receive psilocybin therapy there? Long-term care is typically not an appropriate setting for psychedelic-assisted therapy. The infrastructure, staff expertise, and clinical context are not designed for it. Specialty outpatient delivery is the appropriate setting; transferring an LTC resident for outpatient psychedelic-assisted therapy is uncommon and requires substantial care coordination.

My parent has end-of-life distress — what's the pathway? SAP psilocybin for end-of-life distress is the most established Canadian pathway. End-of-life distress is the original SAP-approved psilocybin indication. Quebec RAMQ Farzin/Stephan precedent provides a public-funding pathway in Quebec. Coordination with palliative care team is essential.

My parent is a veteran — is there VAC coverage? Yes — VAC has an established case-by-case pathway for psychedelic-assisted therapy (predominantly ketamine; some psilocybin SAP) for service-related conditions including PTSD and depression. Older veterans should explore this pathway.

Are there public hospital ketamine programs? Yes — Edmonton Misericordia/Grey Nuns and Vancouver UBC Hospital VCH are publicly-funded outpatient psychiatric ketamine programs that accept older adults meeting clinical criteria. Wait lists exist; referral is through psychiatry.

What if the older adult lacks capacity? Capacity to consent must be established for any psychedelic-assisted therapy. Substitute decision-makers cannot consent on behalf of incapable adults for this kind of intervention; this is consistent with the broader Canadian framework on consent for non-emergency medical interventions.

What's the role of family in preparation and integration? Significant. Particularly for psilocybin SAP end-of-life distress, family presence at preparation and integration sessions and post-session support are clinically meaningful. Caregiver mental health is also part of the picture.

Can I be in long-term care and still do this? LTC residents face substantial logistical and clinical barriers. Specialty outpatient psychedelic-assisted therapy is the appropriate setting; transferring an LTC resident is uncommon and requires care coordination across the LTC facility, the outpatient clinic, and primary care.

Sources

Griffiths RR, Johnson MW, Carducci MA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12):1181-1197. PMID: 27909164.
Ross S, Bossis A, Guss J, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12):1165-1180. PMID: 27909165.
Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Anand A, Mathew SJ, Sanacora G, et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine, 388(25):2315-2325. PMID: 37224135.
Ochs-Ross R, Daly EJ, Zhang Y, et al. (2020). Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression — TRANSFORM-3. Am J Geriatr Psychiatry, 28(2):121-141. PMID: 31734084.
By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc, 71(7):2052-2081. PMID: 37139824.
Canadian Coalition for Seniors' Mental Health (CCSMH). National Guidelines for Seniors' Mental Health: https://ccsmh.ca/
MacQueen GM, Frey BN, Ismail Z, et al. (2016). CANMAT Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations — Late-Life Depression. Can J Psychiatry, 61(9):588-603. PMID: 27486149.
Lapid MI, Burton MC, Chang MT, et al. (2010). Clinical phenomenology and mortality in Charles Bonnet syndrome and other late-life psychiatric considerations — review framework relevant to capacity assessment.
Health Canada — Spravato Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html
Health Canada — SAP psychedelic-assisted psychotherapy announcement: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Statistics Canada — Population estimates and seniors: https://www150.statcan.gc.ca/
Public Health Agency of Canada — Suicide in Canada (older adult demographics): https://www.canada.ca/en/public-health/services/publications/healthy-living/suicide-canada-key-statistics-infographic.html

End-of-Life Distress and Psychedelic-Assisted Therapy — substantially overlapping population
Treatment-Resistant Depression and Psychedelic-Assisted Therapy
PTSD and Psychedelic-Assisted Therapy — aging veterans
Chronic Pain and Psychedelic-Assisted Therapy — frequent older-adult comorbidity
Quebec RAMQ Coverage for Psychedelic Therapy
VAC Coverage for Psychedelic-Assisted Therapy
Edmonton Misericordia/Grey Nuns Public Ketamine
Psilocybin Therapy in Canada
Ketamine Therapy in Canada

Last updated: 2026-05-06

Older Adults and Psychedelic-Assisted Therapy in Canada — Geriatric Considerations

Access and legality vary by jurisdiction